

Original Article
Urology



OPEN ACCESS

Received: Jan 23, 2018

Accepted: Aug 7, 2018

Address for Correspondence:

Byung Ha Chung, MD, PhD

Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 06273, Korea.
E-mail: chung646@yuhs.ac

© 2018 The Korean Academy of Medical Sciences.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Do Kyung Kim <https://orcid.org/0000-0002-3696-8756>
Kyo Chul Koo <https://orcid.org/0000-0001-7303-6256>
Kwang Suk Lee <https://orcid.org/0000-0002-7961-8393>
Yoon Soo Hah <https://orcid.org/0000-0001-6424-4619>
Koon Ho Rha <https://orcid.org/0000-0001-8588-7584>
Sung Joon Hong <https://orcid.org/0000-0002-7622-4153>
Byung Ha Chung <https://orcid.org/0000-0001-9817-3660>

Time to Disease Recurrence Is a Predictor of Metastasis and Mortality in Patients with High-risk Prostate Cancer Who Achieved Undetectable Prostate-specific Antigen Following Robot-assisted Radical Prostatectomy

Do Kyung Kim , Kyo Chul Koo , Kwang Suk Lee , Yoon Soo Hah ,
Koon Ho Rha , Sung Joon Hong , and Byung Ha Chung

Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

ABSTRACT

Background: Robot-assisted radical prostatectomy (RARP) is a feasible treatment option for high-risk prostate cancer (PCa). While patients may achieve undetectable prostate-specific antigen (PSA) levels after RARP, the risk of disease progression is relatively high. We investigated metastasis-free survival, cancer-specific survival (CSS), and overall survival (OS) outcomes and prognosticators in such patients.

Methods: In a single-center cohort of 342 patients with high-risk PCa (clinical stage \geq T3, biopsy Gleason score \geq 8, and/or PSA levels \geq 20 ng/mL) treated with RARP and pelvic lymph node dissection between August 2005 and June 2011, we identified 251 (73.4%) patients (median age, 66.5 years; interquartile range [IQR], 63.0–71.0 years) who achieved undetectable PSA levels ($<$ 0.01 ng/mL) postoperatively. Survival outcomes were evaluated for the entire study sample and in groups stratified according to the time to biochemical recurrence dichotomized at 60 months.

Results: During the median follow-up of 75.9 months (IQR, 59.4–85.8 months), metastasis occurred in 38 (15.1%) patients, most often to the bones, followed by the lymph nodes, lungs, and liver. The 5-year metastasis-free, cancer-specific, and OS rates were 87.1%, 94.8%, and 94.3%, respectively. Multivariate Cox-regression analysis revealed time to recurrence as an independent predictor of metastasis ($P <$ 0.001). Time to metastasis was an independent predictor of OS ($P =$ 0.003). Metastasis-free and CSS rates were significantly lower among patients with recurrence within 60 months of RARP (log-rank $P <$ 0.001).

Conclusion: RARP confers acceptable oncological outcomes for high-risk PCa. Close monitoring beyond 5 years is warranted for early detection of disease progression and for timely adjuvant therapy.

Keywords: Prostate Cancer; Prostatectomy; Recurrence; Survival

Funding

This study was supported by the Young Researcher Program Grant of the National Research Foundation of Korea (NRF-2017R1C1B5017516).

Disclosure

The authors have no potential conflicts of interest to disclose.

Author Contributions

Conceptualization: Kim DK, Koo KC, Chung BH. Data curation: Kim DK, Koo KC. Methodology: Kim DK, Koo KC, Lee KS, Hah YS. Investigation: Kim DK, Koo KC, Lee KS, Hah YS, Rha KH, Hong SJ, Chung BH. Writing - original draft: Kim DK.

INTRODUCTION

With the advent of the prostate-specific antigen (PSA) screening era, an increasing number of newly diagnosed prostate cancer (PCa) cases tend to be assessed as lower-risk disease.¹ Nevertheless, between 20% and 35% of PCa patients in the United States present with clinically high-risk disease.¹⁻³ In these high-risk patients, survival outcomes are heterogeneous, and there is no consensus on the optimal management strategy.⁴

In the last decade, radiotherapy (RT) administered in combination with androgen deprivation therapy (ADT) has been the strategy of choice for the management of localized high-risk PCa. However, with the advancement of minimally invasive surgical techniques, surgery has gained acknowledgement as a feasible alternative.⁵ In a recent study using propensity-score matched analysis to compare oncological outcomes of patients with localized or locally advanced PCa treated with radical prostatectomy (RP) and RT, the two treatments demonstrated comparable cancer-specific survival (CSS) for all risk groups defined by the National Comprehensive Cancer Network (NCCN).⁶ Moreover, robot-assisted radical prostatectomy (RARP) was demonstrated to be a curative treatment option for a subset of high-risk patients with long-term undetectable PSA levels. Another advantage of surgical treatment is the opportunity to perform precise pathological evaluation and use postoperative nomograms, which facilitate the initiation of appropriate and timely adjuvant therapy.⁷ Indeed, 14% to 37% of high-risk PCa patients treated with RP demonstrate favorable pathologic results and better oncological outcomes than those noted among other high-risk patients.⁸⁻¹⁰

Patients with high-risk PCa treated with RP may achieve undetectable PSA levels postoperatively. Compared to patients with a low or intermediate risk, a higher proportion of patients with a high-risk will experience biochemical recurrence (BCR), although the clinical course of patients with BCR is highly variable.¹¹ Specifically, some patients experience rapid clinical progression to metastases, whereas BCR may pose no threat throughout the remaining life span of other patients.¹² Studies have reported time to BCR as a significant prognosticator of cancer-specific mortality (CSM). However, few data are available regarding the relevance of time to BCR in patients with high-risk PCa undergoing RP.^{13,14}

The purpose of the present study was to confirm the feasibility of RARP for high-risk PCa and to investigate the effect of time to disease progression on metastasis and mortality rates in patients with high-risk PCa who achieved undetectable PSA following RARP. To address these issues, we investigated metastasis-free survival (MFS), CSS, and overall survival (OS) outcomes, as well as the prognosticators of these survival endpoints.

METHODS**Patient selection**

We retrospectively reviewed the records of 342 patients treated with RARP and pelvic lymph node dissection between August 2005 and June 2011 at a single tertiary institution. We identified 251 (73.4%) patients with high-risk PCa who achieved undetectable PSA postoperatively, defined as < 0.01 ng/mL by ultrasensitive assay. High-risk PCa was defined as clinical stage \geq T3, biopsy Gleason score \geq 8, and/or PSA levels \geq 20 ng/mL, according to the NCCN guidelines.¹⁵ PCa staging was determined according to the 7th American

Joint Committee on Cancer TNM system, with the definition of distant metastasis based on either demonstrable metastatic deposits on imaging (bone scan, computerized tomography, magnetic resonance imaging, or positron emission tomography) or pathologic confirmation of PCa in tissue samples collected from outside the prostatic fossa. The following exclusion criteria were applied: 1) incomplete clinical data; 2) loss to follow-up; 3) unknown cause of death.

Prognostic factors and outcome variables

All patients had complete clinical and pathological data including age, body mass index (BMI), preoperative PSA levels, clinical stage, biopsy Gleason score, pathological stage with Gleason score, positive surgical margin status, tumor volume, seminal vesicle invasion status, lymph node invasion status, prostatic intraepithelial neoplasia grading, and time to BCR. These patients were further stratified into two groups according to time to BCR dichotomized at 60 months. BCR was defined as the first of two or more consecutive increases in PSA levels of > 0.2 ng/mL noted later than 3 months following surgery. Time to metastasis was defined as the time period from the date of histological diagnosis to the time of metastasis detection. OS was determined as the time elapsed between the date of histological diagnosis and the date of death. For all patients, the survival status and the cause of death were obtained from the National Cancer Registry Database or from the electronic medical records of the treating institution.

Study endpoints

The primary endpoints were the rates of MFS, CSS, and OS, whereas the secondary endpoints included the prognosticators of these survival endpoints.

Statistical analysis

Demographic characteristics of patients and tumors were compared using descriptive statistics including median and interquartile range (IQR). Appropriate comparative tests such as the Student's t-test and the χ^2 test, were used to compare continuous and categorical variables, respectively. Kaplan-Meier curves were used to estimate MFS and OS. Univariate and multivariate analyses were performed using Cox-proportional hazards regression models in order to adjust for potential confounders in predicting survival. Variables considered potential predictors for the purpose of multivariate modeling were selected by univariate analysis. Results regarding prognosticators were expressed in terms of hazard ratio (HR) with 95% confidence intervals (CIs). Statistical analysis was performed using SPSS version 18 (SPSS Inc., Chicago, IL, USA). All tests were two-sided, with statistical significance set at $P < 0.05$.

Ethics statement

This retrospective study was approved by the Institutional Ethics Committee after review of the protocol and procedures employed (approval No. 2014-0112).

RESULTS

Patient demographics

Table 1 summarizes the demographic and clinical characteristics of 251 patients with high-risk PCa who achieved undetectable PSA levels postoperatively. The median age and PSA levels were 66.5 years (IQR, 63.0–71.0 years) and 8.7 ng/mL (IQR, 6.1–18.3 ng/mL), respectively.

Table 1. Preoperative characteristics of patients with high-risk PCa who achieved undetectable PSA following robot-assisted radical prostatectomy

Characteristics	Overall
Age, yr	66.5 (63.0–71.0)
PSA, ng/mL	8.7 (6.1–18.3)
BMI, kg/m ²	24.1 (22.3–25.9)
Clinical tumor stage, No. (%)	
cT1	20 (8.0)
cT2	103 (41.0)
cT3	122 (48.6)
cT4	6 (2.4)
Biopsy Gleason score, No. (%)	
≤ 6	85 (33.9)
7	120 (47.8)
3 + 4	82 (32.7)
4 + 3	38 (15.1)
≥ 8	46 (18.3)
Clinical nodal status, No. (%)	
N0	225 (89.6)
N1	26 (10.4)

PCa = prostate cancer, PSA = prostate-specific antigen, BMI = body mass index.

Postoperative characteristics

The patients were followed-up for a median of 75.9 months (IQR, 59.4–85.8 months) and stratified into two groups according to the time to BCR (dichotomized at 60 months). The incidence of pathological N1 disease was higher in patients who experienced BCR at ≤ 60 months than in those who did not ($P = 0.044$), but no differences between the two groups were noted regarding other postoperative tumor characteristics (Table 2).

Oncological outcomes

The oncological outcomes of our cohort are summarized in Table 3. BCR was observed in 65 (25.9%) patients, with an overall 5-year BCR-free survival rate of 73.9%. Metastasis occurred in 38 (15.1%) patients, mostly to the bones (65.8%), followed by the lymph nodes (36.8%), lungs

Table 2. Postoperative pathological outcomes of patients with high-risk PCa who achieved undetectable PSA following robot-assisted radical prostatectomy

Characteristics	Overall	Time to BCR		P value
		< 60 mon	≥ 60 mon	
No. of patients	251	148 (59.0)	103 (41.0)	NS
Pathologic tumor stage, No. (%)				0.469
pT2	48 (19.1)	30 (20.2)	18 (17.4)	
pT3	183 (72.9)	109 (73.6)	74 (71.8)	
pT4	20 (8.0)	9 (6.2)	11 (10.8)	
Pathologic Gleason score, No. (%)				0.639
≤ 6	44 (17.5)	22 (14.9)	22 (21.4)	
7	127 (50.6)	80 (54.1)	47 (45.6)	
≥ 8	80 (31.9)	46 (31.0)	34 (33.0)	
7 (3 + 4)	86 (34.3)	54 (36.5)	32 (31.1)	0.875
7 (4 + 3)	41 (16.3)	26 (17.6)	15 (14.6)	
Pathologic nodal status, No. (%)				0.044
N0	233 (92.8)	134 (90.5)	99 (96.1)	
N1	18 (7.2)	14 (9.5)	4 (3.9)	
Positive surgical margin, No. (%)	80 (31.9)	50 (33.7)	30 (29.1)	0.132
Tumor volume	1.5 (0.87–2.78)	1.7 (0.95–3.1)	1.2 (0.7–2.4)	0.367
Seminal vesicle invasion, No. (%)	30 (12.0)	20 (13.5)	10 (9.7)	0.090
Lymphovascular invasion, No. (%)	17 (6.9)	8 (5.4)	9 (8.7)	0.149
High grade PIN, No. (%)	159 (63.3)	90 (60.8)	69 (67.0)	0.059
Total follow-up, mon	75.9 (59.4–85.8)	76.4 (63.6–82.5)	74.1 (53.1–81.1)	0.891

PCa = prostate cancer, PSA = prostate-specific antigen, BCR = biochemical recurrence, PIN = prostatic intraepithelial neoplasia.

Table 3. Oncological outcomes of patients with high-risk PCa who achieved undetectable PSA following robot-assisted radical prostatectomy

Characteristics	Overall
BCR, No. (%)	65 (25.9)
BCR-free survival (%), 5-year	73.9
Metastasis, No. (%)	38 (15.1)
Metastatic site, No. (%)	
Bone	25 (65.8)
LN	14 (36.8)
Lung	6 (15.8)
Liver	5 (13.2)
MFS (%), 5-year	87.1
Adjuvant therapy, No. (%)	
None	150 (59.8)
ADT only	31 (12.3)
RT + ADT	70 (27.9)
Causes of death, No. (%)	
Second primary malignancy	14 (5.6)
PCa	7 (2.8)
Cardiopulmonary disease	4 (1.6)
Cancer-specific survival (%), 5-year	94.8
OS (%), 5-year	94.3

PCa = prostate cancer, PSA = prostate-specific antigen, BCR = biochemical recurrence, LN = lymph node, MFS = metastasis-free survival, ADT = androgen deprivation therapy, RT = radiotherapy, OS = overall survival.




Fig. 1. Kaplan-Meier curves for MFS rate according to time to BCR (log-rank $P < 0.001$). MFS = metastasis-free survival, BCR = biochemical recurrence.

(15.8%), and liver (13.2%). Overall, 101 (40.2%) patients received adjuvant treatment with either ADT or RT plus ADT. The 5-year MFS, CSS, and OS rates were 87.1%, 94.8%, and 94.3%, respectively. Patients who exhibited BCR at ≤ 60 months after RARP exhibited significantly lower MFS and OS rates compared to those of patients who did not (log-rank $P < 0.001$; Figs. 1 and 2). The most common cause of death was second primary malignancy, followed by PCa and cardiopulmonary disease. Among the 342 high-risk patients reviewed in our study, 186 (54.4%) patients achieved cure, defined as persistent undetectable PSA levels at the median follow-up.

Perioperative prognosticators of MFS and CSS

Univariate Cox-regression analyses revealed pathologic Gleason score (≥ 8 vs. < 7) (HR, 2.227; 95% CI, 1.197–4.412; $P = 0.011$), pathologic node stage (HR, 2.883; 95% CI, 1.523–5.459;




Fig. 2. Kaplan-Meier curves for OS rate according to time to BCR (log-rank $P < 0.001$). OS = overall survival, BCR = biochemical recurrence.

$P = 0.001$), seminal vesicle invasion (HR, 5.656; 95% CI, 2.003–15.97; $P = 0.001$), shorter time to BCR (HR, 0.956; 95% CI, 0.939–0.973; $P < 0.001$) as an independent predictor of a higher risk of metastasis (Table 4), while a shorter time to BCR (HR, 0.956; 95% CI, 0.925–0.989; $P = 0.009$) and metastasis (HR, 0.857; 95% CI, 0.813–0.903; $P < 0.001$) was revealed to be an independent predictor of a higher risk of CSM (Table 5).

Multivariate Cox-regression analyses revealed longer time to BCR as an independent predictor of a lower risk of metastasis (HR, 0.918; 95% CI, 0.878–0.961; $P < 0.001$) (Table 4), while a longer time to metastasis was revealed to be an independent predictor of a lower risk of CSM (HR, 0.885; 95% CI, 0.816–0.959; $P = 0.003$) (Table 5).

Table 4. Association of perioperative factors with the risk of metastasis among patients with high-risk PCa who achieved undetectable PSA levels following radical prostatectomy

Variables	Univariate			Multivariate		
	HR	95% CI	<i>P</i> value	HR	95% CI	<i>P</i> value
Age, yr	1.012	0.963–1.062	0.646	-	-	-
BMI	1.041	0.917–1.181	0.537	-	-	-
PSA	1.003	0.998–1.009	0.255	-	-	-
Pathologic T stage (\geq pT3 vs. \leq pT2)	2.014	0.707–5.739	0.191	-	-	-
Pathologic Gleason score (\geq 8 vs. $<$ 7)	2.227	1.197–4.142	0.011	2.046	0.556–7.532	0.282
Pathologic Gleason score (7 [4 + 3] vs. 7 [3 + 4])	0.428	0.127–2.019	0.346	-	-	-
Pathologic N stage (N1)	2.883	1.523–5.459	0.001	0.519	0.120–2.244	0.387
Tumor volume	1.053	0.952–1.166	0.316	-	-	-
Positive surgical margin	1.147	0.588–2.237	0.686	-	-	-
Seminal vesicle invasion	5.656	2.003–15.97	0.001	1.626	0.475–5.565	0.439
Lymphovascular invasion	1.914	0.441–8.301	0.386	-	-	-
No. of positive LNs	1.169	0.583–2.234	0.662	-	-	-
High grade PIN	1.055	0.415–2.684	0.911	-	-	-
PSA nadir period	0.992	0.956–1.029	0.661	-	-	-
Time to BCR	0.956	0.939–0.973	< 0.001	0.918	0.878–0.961	< 0.001
Salvage radiation therapy	0.263	0.067–1.032	0.053	0.212	0.032–1.393	0.105

PCa = prostate cancer, PSA = prostate-specific antigen, CI = confidence interval, HR = hazard ratio, BMI = body mass index, LN = lymph node, PIN = prostatic intraepithelial neoplasia, BCR = biochemical recurrence.

Table 5. Association of perioperative factors with the risk of CSM among patients with high-risk PCa who achieved undetectable PSA levels following radical prostatectomy

Variables	Univariate			Multivariate		
	HR	95% CI	P value	HR	95% CI	P value
Age, yr	0.956	0.881-1.037	0.277	-	-	-
BMI	1.055	0.783-1.421	0.724	-	-	-
PSA	1.006	0.994-1.019	0.331	-	-	-
Pathologic T stage (\geq pT3 vs. \leq pT2)	1.334	0.835-2.165	0.223	-	-	-
Pathologic Gleason score (\geq 8 vs. $<$ 7)	1.497	0.136-16.51	0.742	-	-	-
Pathologic Gleason score (7 [4 + 3] vs. 7 [3 + 4])	1.145	0.526-2.211	0.566	-	-	-
Pathologic N stage (N1)	6.581	0.596-72.61	0.124	-	-	-
Tumor volume	3.771	0.323-43.97	0.291	-	-	-
Positive surgical margin	2.129	0.341-13.26	0.419	-	-	-
Seminal vesicle invasion	2.776	0.288-26.73	0.377	-	-	-
Lymphovascular invasion	1.112	0.588-1.937	0.644	-	-	-
No. of positive LNs	2.175	0.562-8.415	0.261	-	-	-
High grade PIN	0.932	0.096-9.051	0.951	-	-	-
PSA nadir period	0.539	0.137-2.121	0.376	-	-	-
Time to BCR	0.956	0.925-0.989	0.009	0.948	0.892-1.007	0.083
Salvage radiation therapy	2.286	0.198-26.43	0.509	-	-	-
Time to metastasis	0.857	0.813-0.903	$<$ 0.001	0.885	0.816-0.959	0.003

CSM = cancer-specific mortality, PCa = prostate cancer, PSA = prostate-specific antigen, HR = hazard ratio, CI = confidence interval, BMI = body mass index, LN = lymph node, PIN = prostatic intraepithelial neoplasia, BCR = biochemical recurrence.

DISCUSSION

RP is one of the most commonly used treatments for patients with localized PCa and has been proven to provide favorable prognosis in a subset of high-risk patients.¹⁶⁻¹⁸ In the present study, we confirmed that RP may confer undetectable PSA levels postoperatively, and, consequently, a chance for cure in a substantial proportion of patients. Pompe et al.¹⁹ examined oncologic outcome of high-risk or very high-risk patients who underwent RP. The authors reported that despite the relatively poor prognosis of patients with high-risk PCa, RP results in favorable 5 and 8 years MFS, CSM-free survival and OS rates. At the same time, our data suggest that RP alone may not be sufficient for local control of PCa, and that maximal oncological control is rather achieved by timely administration of multidisciplinary adjuvant treatment, even beyond 5 years postoperatively. Amling et al.²⁰ suggested patients undergoing RP should be subjected to long-term follow-up to allow the option of early intervention should progression occur due to a significant number of patients, including those with organ confined cancers which may exhibit disease progression even after 5 years.

We observed that 73.9% of patients achieved undetectable PSA levels postoperatively, which adds to the literature regarding the feasibility of RP for the treatment of high-risk disease. Specifically, RP provides several distinct advantages over ADT or RT. First, accurate pathological staging following RP enables timely administration of adjuvant therapy, at the same time avoiding morbidities associated with unnecessary adjuvant treatment.²¹ Recent studies have shown that up to 35% of patients are inaccurately staged, and up to 50% of patients originally identified to have high-risk disease demonstrate lower-risk disease on final pathological review.^{11,22} Second, RP may provide superior local cancer control compared to that allowed by other treatment modalities. Boorjian et al.¹⁶ evaluated the long-term survival outcomes of high-risk PCa treated with RP or external beam RT with or without adjuvant ADT, and observed that patients treated with RT had a significantly increased risk of all-cause mortality compared to that noted among patients who received RP. Third, RP offers better health-related quality of life (HRQoL). Indeed, a long-term assessment of HRQoL

in men receiving RT and brachytherapy showed that their prostate-specific HRQoL scores continued to decline, whereas those of RP patients remained relatively stable or gradually improved.²³ Fourth, men undergoing RP are less likely to require ADT, and have significantly longer ADT-free survival compared to the values noted in patients undergoing external beam RT.⁵ Lastly, primary tumors have been suggested to play a significant role in tumor shedding and cytokine/growth factor production. In this respect, the advantage of RP is that it provides definitive tumor debulking, which may improve overall outcomes.²⁴

In our study, patients were stratified according to the time to BCR, dichotomized at 60 months. The NCCN guideline recommends closed follow-up for up to 5 years, followed by annual follow-up for subsequent years.¹⁵ Our results indicate that BCR may occur even after 60 months in high-risk patients. Therefore, we investigated the subgroup of patients who would benefit from observation beyond 5 years. We found a marginal difference between the two groups regarding pathologic nodal status. However, there were no differences in pathologic features well known to affect oncological outcomes, namely tumor stage, tumor grade, and positive surgical margin status. In particular, there was no significant difference in pathologic Gleason score between 7 (4 + 3) and 7 (3 + 4). However, we did find differences in MFS and OS rates according to time to BCR. Specifically, patients who exhibited BCR within < 60 months after surgery had significantly lower MFS and OS rates. Briganti et al.¹³ evaluated the role of time to BCR in CSM and observed that patients who experienced BCR within 3 years from surgery had significantly higher CSM rates than those noted among patients who developed BCR at a later time. Freedland et al.¹⁴ also found that the time to BCR following surgery was significantly associated with CSM, and that stratifying patients according to BCR dichotomized at 3 years after surgery provided the best risk stratification approach. The difference between the cutoff period reported by Freedland et al.¹⁴ (3 years) and that observed in our study (60 months, i.e., 5 years) may be presumed to arise from the difference in the study cohorts, and specifically because we only included patients who achieved undetectable PSA levels following RP. We also noted that the time to metastasis was a significant prognosticator of the risk of CSM, in accordance with the observations of Pound et al.²⁵, who reported that, after the development of metastatic disease, the actuarial median time until death due to PCa was 5 years, and that time to metastasis was an important determinant of CSM.

Our findings have important clinical implications. In our study, 41% of patients experienced BCR later than 5 years following RARP. The NCCN guideline recommends that PSA levels should be monitored every 6 to 12 months until 5 years postoperatively, and annually thereafter.¹⁵ Our observation that a substantial proportion of patients are likely to experience BCR later than 5 years after surgery suggests that the monitoring interval beyond 5 years postoperatively should be shortened for high-risk PCa patients even if PSA levels remain undetectable beyond this period, in order to enable early detection of disease progression and timely administration of multidisciplinary adjuvant treatment. Finally, our findings indicate that the time from RP to BCR is a prognosticator for MFS and OS and may therefore be utilized as a proxy for decision making regarding the length of monitoring intervals (in months).

Our study has several limitations. First, its retrospective nature precludes exclusion of potential selection bias regarding the indication for surgical treatment, which was made at the discretion of the treating surgeon. Second, there was discrepancy regarding the monitoring intervals, adjuvant treatment protocol, and treatment duration. Third, patients included in our study received RARP performed by different surgeons, albeit at the same institution, which may have affected the time to BCR and postoperative outcomes such as

positive surgical margin or pathologic nodal status. Indeed, Klein et al.²⁶ reported that the surgeon's experience, independent of surgical volume, affects BCR. However, we consider this aspect as an inherent bias of data collected in the clinical setting, which, in turn, may reflect everyday clinical practice in general. Finally, the median follow-up period was 75.9 months, which is relatively short to draw definitive conclusions regarding MFS or CSS.

In conclusion, a substantial proportion of high-risk PCa patients may achieve undetectable PSA levels following RP. Nevertheless, the risk of BCR and metastasis is relatively high. We confirmed that time to BCR and metastasis were direct or indirect prognosticators of survival rates, and may therefore, be utilized as a proxy for decision making regarding monitoring intervals. Considering that a substantial proportion of patients with postoperatively undetectable PSA are likely to experience BCR later than 60 months after surgery, close monitoring even beyond this period is warranted to enable early detection of disease progression and timely administration of multidisciplinary adjuvant treatment.

REFERENCES

- Cooperberg MR, Cowan J, Broering JM, Carroll PR. High-risk prostate cancer in the United States, 1990–2007. *World J Urol* 2008;26(3):211-8.
[PUBMED](#) | [CROSSREF](#)
- Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR; CaPSURE. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). *J Urol* 2003;170(6 Pt 2):S21-5.
[PUBMED](#) | [CROSSREF](#)
- Shao YH, Demissie K, Shih W, Mehta AR, Stein MN, Roberts CB, et al. Contemporary risk profile of prostate cancer in the United States. *J Natl Cancer Inst* 2009;101(18):1280-3.
[PUBMED](#) | [CROSSREF](#)
- Chung BH. The role of radical prostatectomy in high-risk prostate cancer. *Prostate Int* 2013;1(3):95-101.
[PUBMED](#) | [CROSSREF](#)
- Meng MV, Elkin EP, Latini DM, Duchane J, Carroll PR. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). *J Urol* 2005;173(5):1557-61.
[PUBMED](#) | [CROSSREF](#)
- Koo KC, Cho JS, Bang WJ, Lee SH, Cho SY, Kim SI, et al. Cancer-specific mortality among korean men with localized or locally advanced prostate cancer treated with radical prostatectomy versus radiotherapy: a multi-center study using propensity scoring and competing risk regression analyses. *Cancer Res Treat* 2018;50(1):129-37.
[PUBMED](#) | [CROSSREF](#)
- Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. *J Clin Oncol* 1999;17(5):1499-507.
[PUBMED](#) | [CROSSREF](#)
- Briganti A, Joniau S, Gontero P, Abdollah F, Passoni NM, Tombal B, et al. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. *Eur Urol* 2012;61(3):584-92.
[PUBMED](#) | [CROSSREF](#)
- Musch M, Pluemer J, Roggenbuck U, Klevecka V, Kroepfl D. Clinically high-risk prostate cancer patients comprise a relevant number of cancers with overall favorable tumor characteristics. *World J Urol* 2015;33(1):85-92.
[PUBMED](#) | [CROSSREF](#)
- Walz J, Joniau S, Chun FK, Isbarn H, Jeldres C, Yossepowitch O, et al. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. *BJU Int* 2011;107(5):765-70.
[PUBMED](#) | [CROSSREF](#)
- Ploussard G, Masson-Lecomte A, Beauval JB, Ouzzane A, Bonniol R, Buge F, et al. Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification. *Urology* 2011;78(3):607-13.
[PUBMED](#) | [CROSSREF](#)

12. Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. *Eur Urol* 2007;51(5):175-84.
[PUBMED](#) | [CROSSREF](#)
13. Briganti A, Karnes RJ, Gandaglia G, Spahn M, Gontero P, Tosco L, et al. Natural history of surgically treated high-risk prostate cancer. *Urol Oncol* 2015;33(4):163.e7-13.
[PUBMED](#) | [CROSSREF](#)
14. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. *JAMA* 2005;294(4):433-9.
[PUBMED](#) | [CROSSREF](#)
15. Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, et al. Prostate cancer, version 1.2016. *J Natl Compr Canc Netw* 2016;14(1):19-30.
[PUBMED](#) | [CROSSREF](#)
16. Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. *Cancer* 2011;117(13):2883-91.
[PUBMED](#) | [CROSSREF](#)
17. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. *Cancer* 2010;116(22):5226-34.
[PUBMED](#) | [CROSSREF](#)
18. Lee DH, Jung HB, Chung MS, Lee SH, Chung BH. The change of prostate cancer treatment in Korea: 5 year analysis of a single institution. *Yonsei Med J* 2013;54(1):87-91.
[PUBMED](#) | [CROSSREF](#)
19. Pompe RS, Karakiewicz PI, Tian Z, Mandel P, Steuber T, Schlomm T, et al. Oncologic and functional outcomes after radical prostatectomy for high or very high risk prostate cancer: European validation of the current NCCN® guideline. *J Urol* 2017;198(2):354-61.
[PUBMED](#) | [CROSSREF](#)
20. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. *J Urol* 2000;164(1):101-5.
[PUBMED](#) | [CROSSREF](#)
21. Kang HW, Lee JY, Kwon JK, Jeh SU, Jung HD, Choi YD. Current status of radical prostatectomy for high-risk prostate cancer. *Korean J Urol* 2014;55(10):629-35.
[PUBMED](#) | [CROSSREF](#)
22. Lee BH, Kibel AS, Ciezki JP, Klein EA, Reddy CA, Yu C, et al. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence. *Eur Urol* 2015;67(2):204-9.
[PUBMED](#) | [CROSSREF](#)
23. Jayadevappa R, Chhatre S, Whittington R, Bloom BS, Wein AJ, Malkowicz SB. Health-related quality of life and satisfaction with care among older men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy. *BJU Int* 2006;97(5):955-62.
[PUBMED](#) | [CROSSREF](#)
24. Kaplan RN, Raffi S, Lyden D. Preparing the "soil": the premetastatic niche. *Cancer Res* 2006;66(23):11089-93.
[PUBMED](#) | [CROSSREF](#)
25. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. *JAMA* 1999;281(17):1591-7.
[PUBMED](#) | [CROSSREF](#)
26. Klein EA, Bianco FJ, Serio AM, Eastham JA, Kattan MW, Pontes JE, et al. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. *J Urol* 2008;179(6):2212-6.
[PUBMED](#) | [CROSSREF](#)